Loading cancer entity…
Loading cancer entity…
Clinical trials
805 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00454363 | Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2020 | clinicaltrials |
| NCT04029428 | Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression(POLNETS_PRRT) | unknown | Phase 2 | 150 | University of Warmia and MazuryOTHER | 1 | Apr 1, 2020 |
| clinicaltrials |
| NCT04296149 | Beta- Probe and Surgery in GEP NET: Evaluation of a New Probe(RADIONET) | completed | Phase 2 | 5 | European Institute of OncologyOTHER | 1 | Mar 5, 2020 | clinicaltrials |
| NCT03422029 | Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients | unknown | Phase 2 | 20 | Peking UniversityOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT00939523 | Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy | completed | Phase 2 | 9 | Cedars-Sinai Medical CenterOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT00985946 | Study of Panobinostat in Patients With Neuroendocrine Tumors | terminated | Phase 2 | 15 | University of Wisconsin, MadisonOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT00501540 | Lithium for Low-Grade Neuroendocrine Tumors | completed | Phase 2 | 15 | University of Wisconsin, MadisonOTHER | 1 | Nov 26, 2019 | clinicaltrials |
| NCT01967537 | Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors | completed | Phase 2 | 341 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2019 | clinicaltrials |
| NCT02177773 | GA-68 DOTA-TOC of Somatostatin Positive Malignancies(DOTA-TOC) | terminated | Phase 1 / Phase 2 | 300 | University of California, San FranciscoOTHER | 1 | Nov 12, 2019 | clinicaltrials |
| NCT02162446 | 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET | completed | Phase 1 / Phase 2 | 12 | IpsenINDUSTRY | 1 | Oct 2, 2019 | clinicaltrials |
| NCT01456078 | A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors(ILUMINET) | completed | Phase 2 | 60 | Lund University HospitalOTHER | 1 | Sep 30, 2019 | clinicaltrials |
| NCT00781911 | A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer | completed | Phase 2 | 43 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 20, 2019 | clinicaltrials |
| NCT01648465 | Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors | terminated | Phase 2 | 25 | Hellenic Cooperative Oncology GroupOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT00323076 | [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours | terminated | Phase 1 / Phase 2 | 92 | AHS Cancer Control AlbertaOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT01280201 | Pazopanib as Single Agent in Advanced NETs | completed | Phase 2 | 44 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | May 29, 2019 | clinicaltrials |
| NCT03963193 | Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type | unknown | Phase 2 | 112 | Henan Cancer HospitalOTHER_GOV | 0 | May 24, 2019 | clinicaltrials |
| NCT02231762 | Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET(SONNET) | completed | Phase 2 | 57 | IpsenINDUSTRY | 2 | May 6, 2019 | clinicaltrials |
| NCT01283542 | Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.(Passion I) | completed | Phase 2 | 20 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 26, 2019 | clinicaltrials |
| NCT01290536 | Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases | completed | Phase 2 | 42 | Nicholas Fidelman, MDOTHER | 0 | Mar 1, 2019 | clinicaltrials |
| NCT00605566 | Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors | completed | Phase 2 | 22 | University Health Network, TorontoOTHER | 1 | Feb 19, 2019 | clinicaltrials |
| NCT00688623 | RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe(RAMSETE/CDE16) | completed | Phase 2 | 73 | Novartis PharmaceuticalsINDUSTRY | 8 | Jan 25, 2019 | clinicaltrials |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | completed | Phase 2 | 252 | National Cancer Institute (NCI)NIH | 2 | Jan 25, 2019 | clinicaltrials |
| NCT01994213 | A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor | terminated | Phase 2 | 53 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 22, 2019 | clinicaltrials |
| NCT01262235 | A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients | completed | Phase 1 / Phase 2 | 68 | Arbutus Biopharma CorporationINDUSTRY | 1 | Jan 16, 2019 | clinicaltrials |
| NCT01435122 | A Study of Axitinib in Advanced Carcinoid Tumors | completed | Phase 2 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 2, 2018 | clinicaltrials |
| NCT00019474 | Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer | completed | Phase 2 | 60 | Montefiore Medical CenterOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT03629847 | Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue | unknown | Phase 1 / Phase 2 | 30 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Aug 14, 2018 | clinicaltrials |
| NCT02279602 | Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study | completed | Phase 2 | 7 | Mateon TherapeuticsINDUSTRY | 1 | Apr 17, 2018 | clinicaltrials |
| NCT01024387 | AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 8, 2018 | clinicaltrials |
| NCT02299089 | Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) | completed | Phase 2 | 12 | Camurus ABINDUSTRY | 4 | Dec 15, 2017 | clinicaltrials |
| NCT02132468 | A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers(GI-NETorPNET) | completed | Phase 2 | 18 | Mateon TherapeuticsINDUSTRY | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00903396 | Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer | terminated | Phase 2 | 7 | Alliance for Clinical Trials in OncologyOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT02108782 | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 0 | Jul 19, 2017 | clinicaltrials |
| NCT00001191 | The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid | completed | Phase 2 | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT03204019 | A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor | unknown | Phase 2 | 60 | Chinese Academy of Medical SciencesOTHER | 1 | Jun 29, 2017 | clinicaltrials |
| NCT01719861 | Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors | terminated | Phase 2 | 6 | Joel NealOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT00947167 | A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | terminated | Phase 2 | 4 | Pamela L. KunzOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00050349 | EPO906 in Carcinoid and Other Neuroendocrine Tumors | completed | Phase 2 | 33 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 1, 2017 | clinicaltrials |
| NCT00398320 | Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors | completed | Phase 2 | 40 | Pamela L. KunzOTHER | 1 | Mar 1, 2017 | clinicaltrials |
| NCT00093782 | Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2017 | clinicaltrials |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | terminated | Phase 2 | 2 | Emory UniversityOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT01731925 | A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors(SUNLAND) | unknown | Phase 2 | 44 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 2 | Jan 31, 2017 | clinicaltrials |
| NCT00965250 | Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy | completed | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2016 | clinicaltrials |
| NCT01374451 | Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET(COOPERATE-2) | terminated | Phase 2 | 160 | Novartis PharmaceuticalsINDUSTRY | 19 | Dec 20, 2016 | clinicaltrials |
| NCT02078843 | Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors(GaIN) | terminated | Phase 1 / Phase 2 | 54 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Sep 7, 2016 | clinicaltrials |
| NCT01620138 | Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas | completed | Phase 2 / Phase 3 | 21 | Universidade Federal do Rio de JaneiroOTHER | 1 | Aug 22, 2016 | clinicaltrials |
| NCT00869050 | Capecitabine and Temozolomide for Neuroendocrine Cancers | completed | Phase 2 | 41 | Columbia UniversityOTHER | 1 | Jul 25, 2016 | clinicaltrials |
| NCT01048086 | 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET) | withdrawn | Phase 2 | 0 | University of IowaOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT00416767 | Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery | completed | Phase 2 | 20 | Federation Francophone de Cancerologie DigestiveOTHER | 0 | May 30, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Apr 3, 2020source: clinicaltrials